Susan Knox

Publications

• Immunotherapy and Radiation
  Hiniker, S. M., & Knox, S. J. (2014). Immunotherapy and Radiation. SEMINARS IN ONCOLOGY, 41(6), 702-713.
• The implications of hyponitroxia in cancer.
  Oronsky, B., Fanger, G. R., Oronsky, N., Knox, S., & Scicinski, J. (2014). The implications of hyponitroxia in cancer. Translational oncology, 7(2), 167-173.
• The implications of hyponitroxia in cancer
  Oronsky, B., Fanger, G., Oronsky, N., Knox, S. J., & Scicinski, J. (2014). The implications of hyponitroxia in cancer. Translational Oncology, 7(2).
• Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients. Reid, T., Dad, S., Korn, R., Oronsky, B., Knox, S., & Scicinski, J. (2014). Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients. Case reports in oncology, 7(1), 79-85.
  
• Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment. Oronsky, B., Oronsky, N., Knox, S., Fanger, G., & Scicinski, J. (2014). Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment. Anti-cancer agents in medicinal chemistry, 14(8), 1121-1127.
  
• Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., & Knox, S. J. (2014). Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy. Biochemical and Biophysical Research Communications, 447(3).
  
• Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients Reid, T., Dad, S., Korn, R., Oronsky, G., Knox, S. J., & Scicinski, J. (2014). Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients. Case Reports in Oncology, 7(1).
  
• Topical hypochlorite ameliorates NF-kappa B-mediated skin diseases in mice Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. J., & Kim, S. K. (2013). Topical hypochlorite ameliorates NF-kappa B-mediated skin diseases in mice. JOURNAL OF CLINICAL INVESTIGATION, 123(12), 5361-5370.
  
• Radioprotection and Cell Cycle Arrest of Intestinal Epithelial Cells by Darinaparsin, a Tumor Radiosensitizer Tian, J., Doi, H., Saar, M., Santos, J., Li, X., & Knox, S. J. (2013). Radioprotection and Cell Cycle Arrest of Intestinal Epithelial Cells by Darinaparsin, a Tumor Radiosensitizer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(5), 1179-1185.
  
• Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line Parker, J. J., Jones, J. C., Strober, S., & Knox, S. J. (2013). Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. CLINICAL IMMUNOLOGY, 148(1), 44-55.
  
• Phase I Study of a Modified Regimen of (90)Yttrium-Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+Non-Hodgkin Lymphoma Vaklavas, C., Meredith, R. F., Shen, S., Knox, S. J., Micallef, I. N., & Forero-Torres, A. (2013). Phase I Study of a Modified Regimen of (90)Yttrium-Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+Non-Hodgkin Lymphoma. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 28(5), 370-379.
  
• Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm Paulmurugan, R., Oronsky, B., Brouse, C. F., Reid, T., Knox, S., & Scicinski, J. (2013). Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm. THERANOSTICS, 3(6), 437-447.
  
• Topical hypochlorite ameliorates NF-kB-mediated skin diseases in mice Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. K., & Kim, S. K. (2013). Topical hypochlorite ameliorates NF-kB-mediated skin diseases in mice. The Journal of Clinical Investigation, 123(12).
  
• A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., & Knox, S. J. (2012). A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. TRANSLATIONAL ONCOLOGY, 5(6), 404-407.
  
• The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents Oronsky, B. T., Reid, T., Knox, S. J., & Scicinski, J. J. (2012). The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents. TRANSLATIONAL ONCOLOGY, 5(4), 226-229.
  
• Mitigation of Radiation-Induced Dermatitis by Activation of Aldehyde Dehydrogenase 2 Using Topical Alda-1 in Mice Ning, S., Budas, G. R., Churchill, E. N., Chen, C.-H., Knox, S. J., & Mochly-Rosen, D. (2012). Mitigation of Radiation-Induced Dermatitis by Activation of Aldehyde Dehydrogenase 2 Using Topical Alda-1 in Mice. RADIATION RESEARCH, 178(1), 69-74.
  
• Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer Tian, J., Zhao, H., Nolley, R., Reese, S. W., Young, S. R., & Knox, S. J. (2012). Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer. CLINICAL CANCER RESEARCH, 18(12), 3366-3376.
  
• Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy-A Review Oronsky, B. T., Scicinski, J. J., Reid, T., & Knox, S. (2012). Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy-A Review. TRANSLATIONAL ONCOLOGY, 5(3), 133-140.
  
• Abscopal Effect in a Patient with Melanoma Hiniker, S. M., Chen, D. S., & Knox, S. J. (2012). Abscopal Effect in a Patient with Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 366(21), 2035-2035.
  
• Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials Ning, S., Bednarski, M., Oronsky, B., Scicinski, J., Saul, G., & Knox, S. J. (2012). Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials. CANCER RESEARCH, 72(10), 2600-2608.
  
• Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review Oronsky, B. T., Knox, S. J., & Scicinski, J. J. (2012). Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review. TRANSLATIONAL ONCOLOGY, 5(2), 66-71.
  
• Six degrees of separation: the oxygen effect in the development of radiosensitizers. Oronsky, B. T., Knox, S. J., & Scicinski, J. (2011). Six degrees of separation: the oxygen effect in the development of radiosensitizers. Translational oncology, 4(4), 189-198.
  
• Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status Tian, J., Peehl, D. M., Zheng, W., & Knox, S. J. (2010). Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. CANCER LETTERS, 298(2), 231-237.
  
• In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., & Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324-4332.
  
• Anti-alpha v Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats Ning, S., Tian, J., Marshall, D. J., & Knox, S. J. (2010). Anti-alpha v Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats. CANCER RESEARCH, 70(19), 7591-7599.
  
• SODIUM SELENITE RADIOSENSITIZES HORMONE-REFRACTORY PROSTATE CANCER XENOGRAFT TUMORS BUT NOT INTESTINAL CRYPT CELLS IN VIVO Tian, J., Ning, S., & Knox, S. J. (2010). SODIUM SELENITE RADIOSENSITIZES HORMONE-REFRACTORY PROSTATE CANCER XENOGRAFT TUMORS BUT NOT INTESTINAL CRYPT CELLS IN VIVO. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(1), 230-236.
  
• Metalloporphyrin Synergizes with Ascorbic Acid to Inhibit Cancer Cell Growth Through Fenton Chemistry Tian, J., Peehl, D. M., & Knox, S. J. (2010). Metalloporphyrin Synergizes with Ascorbic Acid to Inhibit Cancer Cell Growth Through Fenton Chemistry. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 25(4), 439-448.
  
• I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma Iagaru, A., Mittra, E. S., Ganjoo, K., Knox, S. J., & Goris, M. L. (2010). I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. MOLECULAR IMAGING AND BIOLOGY, 12(2), 198-203.
  
• Impact of Rituximab Treatment on Y-90-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma Shen, S., Forero, A., Meredith, R. F., Shah, J. J., Knox, S. J., & LoBuglio, A. F. (2010). Impact of Rituximab Treatment on Y-90-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma. JOURNAL OF NUCLEAR MEDICINE, 51(1), 150-157.
  
• Impact of Radiation on Immunotherapy Targets Jones, J. C., & Knox, S. J. (2009). Impact of Radiation on Immunotherapy Targets. JOURNAL OF IMMUNOTHERAPY, 32(9), 971-972.
  
• Lanreotide promotes apoptosis and is not radioprotective in GH3 cells Ning, S., Knox, S. J., Harsh, G. R., Culler, M. D., & Katznelson, L. (2009). Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. ENDOCRINE-RELATED CANCER, 16(3), 1045-1055.
  
• Identification of Novel Radiation Induced Immune Signaling Changes in Antigen Presenting Cells Parker, J. J., Jones, J. C., Strober, S., & Knox, S. (2009). Identification of Novel Radiation Induced Immune Signaling Changes in Antigen Presenting Cells. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S545-S545.
  
• Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer Bhattacharyya, R. S., Husbeck, B., Feldman, D., & Knox, S. J. (2008). Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(3), 935-940.
  
• Risks to normal tissues from radionuclide therapy Meredith, R., Wessels, B., & Knox, S. (2008). Risks to normal tissues from radionuclide therapy. SEMINARS IN NUCLEAR MEDICINE, 38(5), 347-357.
  
• Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K., & Knox, S. J. (2008). Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. MOLECULAR CANCER THERAPEUTICS, 7(6), 1569-1578.
  
• CNTO 95, a monoclonal antibody against alpha v integrins, enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K., & Knox, S. J. (2007). CNTO 95, a monoclonal antibody against alpha v integrins, enhances the therapeutic efficacy of fractionated radiation therapy in vivo. MOLECULAR CANCER THERAPEUTICS, 6(12), 3537S-3537S.
  
• MIRD continuing education: Bystander and low-dose-rate effects: Are these relevant to Radionuclide therapy? Sgouros, G., Knox, S. J., Joiner, M. C., Morgan, W. F., & Kassis, A. I. (2007). MIRD continuing education: Bystander and low-dose-rate effects: Are these relevant to Radionuclide therapy?. JOURNAL OF NUCLEAR MEDICINE, 48(10), 1683-1691.
  
• Expression and function of erythropoietin receptors in tumors - Implications for the use of erythropoiesis-stimulating agents in cancer patients Sinclair, A. M., Todd, M. D., Forsythe, K., Knox, S. J., Elliott, S., & Begley, C. G. (2007). Expression and function of erythropoietin receptors in tumors - Implications for the use of erythropoiesis-stimulating agents in cancer patients. CANCER, 110(3), 477-488.
  
• Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis Ning, S., Chen, Z., Dirks, A., Husbeck, B., Hsu, M., & Knox, S. J. (2007). Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis. RADIATION RESEARCH, 168(1), 125-133.
  
• Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., & Knox, S. J. (2007). Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. BLOOD, 109(11), 4655-4662.
  
• Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action Husbeck, B., Bhattacharyya, R. S., Feldman, D., & Knox, S. J. (2006). Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. MOLECULAR CANCER THERAPEUTICS, 5(8), 2078-2085.
  
• Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma Ning, S., & Knox, S. J. (2006). Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 65(2), 493-498.
  
• Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer Street, H. H., Goris, M. L., Fisher, G. A., Wessels, B. W., Cho, C., & Knox, S. J. (2006). Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 21(3), 243-256.
  
• Radiation sensitization with redox modulators: A promising approach Rosenberg, A., & Knox, S. (2006). Radiation sensitization with redox modulators: A promising approach. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 64(2), 343-354.
  
• Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells Husbeck, B., Nonn, L., Peehl, D. M., & Knox, S. J. (2006). Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. PROSTATE, 66(2), 218-225.
  
• Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation Patel, D. A., Kochanski, J., Suen, A. W., Fajardo, L. F., Hancock, S. L., & Knox, S. J. (2006). Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. CANCER, 106(3), 718-725.
  
• Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma Meredith, R. F., & Knox, S. J. (2006). Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(2), S15-S22.
  
• A preliminary report of a phase I study of Zevalin (R) using a modified treatment regimen for relapsed or refractory CD20+B-cell follicular or transformed non-Hodgkin's lymphoma (NHL) Forero-Torres, A., Shah, J., Besh, S., Knox, S., Micallef, I., & Meredith, R. (2005). A preliminary report of a phase I study of Zevalin (R) using a modified treatment regimen for relapsed or refractory CD20+B-cell follicular or transformed non-Hodgkin's lymphoma (NHL). BLOOD, 106(11), 280B-280B.
  
• Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab Kaminski, M. S., Radford, J. A., Gregory, S. A., Leonard, J. P., Knox, S. J., & Wahl, R. L. (2005). Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. JOURNAL OF CLINICAL ONCOLOGY, 23(31), 7985-7993.
  
• Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., & Coleman, M. (2005). Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 23(30), 7565-7573.
  
• Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I-131 tositumomab Bennett, J. M., Kaminski, M. S., Leonard, J. P., Vose, J. M., Zelenetz, A. D., & Capizzi, R. L. (2005). Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I-131 tositumomab. BLOOD, 105(12), 4576-4582.
  
• Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing Husbeck, B., Peehl, D. M., & Knox, S. J. (2005). Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. FREE RADICAL BIOLOGY AND MEDICINE, 38(1), 50-57.
  
• Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia Ning, S. C., Hartley, C., Molineux, G., & Knox, S. J. (2005). Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. CANCER RESEARCH, 65(1), 284-290.
  
• The radioisotope contributes significantly to the activity of radioimmunotherapy Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., & Knox, S. J. (2004). The radioisotope contributes significantly to the activity of radioimmunotherapy. CLINICAL CANCER RESEARCH, 10(23), 7792-7798.
  
• Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier Wartchow, C. A., Alters, S. E., Garzone, P. D., Li, L. Y., Choi, S., & Cleland, J. L. (2004). Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier. PHARMACEUTICAL RESEARCH, 21(10), 1880-1885.
  
• Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide Ning, S. C., & Knox, S. J. (2004). Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60(1), 197-203.
  
• Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors Maxim, P. G., Carson, J. Jl., Ning, S. C., Knox, S. J., Boyer, A. L., & Walleczek, J. (2004). Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors. RADIATION RESEARCH, 162(2), 185-193.
  
• Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer Knox, S., Fisher, G., Wessels, B., Cho, C., Hernandez, M. C., & Goris, M. (2004). Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 19(4), 528-528.
  
• Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma Hernandez, M. C., & Knox, S. J. (2004). Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 59(5), 1274-1287.
  
• Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., & Meredith, R. F. (2004). Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. BLOOD, 104(1), 227-236.
  
• Dosimetry model for radioactivity localized to intestinal mucosa Fisher, D., Rajon, D., Breitz, H., Goris, M., Bolch, W., & Knox, S. (2004). Dosimetry model for radioactivity localized to intestinal mucosa. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 19(3), 293-307.
  
• A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles Li, L. Y., Wartchow, C. A., Danthi, S. N., Shen, Z. M., DeChene, N., & Knox, S. J. (2004). A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(4), 1215-1227.
  
• HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma Kim, Y. H., Obitz, E., Iversen, L., Oesterborg, A., Whittaker, S., & Knox, S. J. (2004). HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 122(3), A57-A57.
  
• Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells Li, L. Y., Steinauer, K. K., Dirks, A. J., Husbeck, B., Gibbs, I., & Knox, S. J. (2003). Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells. RADIATION RESEARCH, 160(6), 617-621.
  
• Radiobiology of radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) Hernandez, M. C., & Knox, S. J. (2003). Radiobiology of radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin). SEMINARS IN ONCOLOGY, 30(6), 6-10.
  
• Higher doses of Rituxan (R) alter pharmacokinetics and biodistribution of Zevalin (R) but may increase responses; a preliminary report of a phase I study of Zevalin (R) using a modified treatment regimen for relapsed or refractory CD20+B-cell follicular/transformed non-Hodgkin's lymphoma. Forero-Torres, A., Besh, S., Knox, S., Micallef, I., Wiseman, G., & Meredith, R. (2003). Higher doses of Rituxan (R) alter pharmacokinetics and biodistribution of Zevalin (R) but may increase responses; a preliminary report of a phase I study of Zevalin (R) using a modified treatment regimen for relapsed or refractory CD20+B-cell follicular/transformed non-Hodgkin's lymphoma. BLOOD, 102(11), 408A-408A.
  
• Long-term results of a randomized trial comparing Tositumomab and Iodine-131 Tositumomab (BEXXAR (R)) with Tositumomab alone in patients with relapsed or refractory low-grade (LG) or transformed low grade (T-LG) Non-Hodgkin's Lymphoma (NHL). Davis, T., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., & Knox, S. (2003). Long-term results of a randomized trial comparing Tositumomab and Iodine-131 Tositumomab (BEXXAR (R)) with Tositumomab alone in patients with relapsed or refractory low-grade (LG) or transformed low grade (T-LG) Non-Hodgkin's Lymphoma (NHL). BLOOD, 102(11), 405A-406A.
  
• Cell surface receptor-targeted dextran-coated liposomes for the treatment of solid tumors. Wartchow, C. A., Alters, S. E., Choi, S., DeChene, N. E., Doede, T., & Knox, S. J. (2003). Cell surface receptor-targeted dextran-coated liposomes for the treatment of solid tumors. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 226, U468-U468.
  
• Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma Yuen, A. R., Higgins, J. P., Baker, R., Kamel, O. W., Warnke, R. A., & Knox, S. J. (2003). Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma. HUMAN PATHOLOGY, 34(4), 381-384.
  
• Pretarget radioimmunotherapy (RIT) with anti-CD20 fusion protein in patients with non-Hodgkin's lymphoma (NHL). Meredith, R., Shen, S., Breitz, H., Fisher, D., Goris, M., & Picozzi, V. (2002). Pretarget radioimmunotherapy (RIT) with anti-CD20 fusion protein in patients with non-Hodgkin's lymphoma (NHL). JOURNAL OF NUCLEAR MEDICINE, 43(5), 116P-117P.
  
• Synthesis of multivalent nanoparticles for use in targeting vascular receptors. Danthi, S. N., Li, L. Y., Ning, S. C., Choi, H. S., Wartchow, C. A., & Bednarski, M. D. (2002). Synthesis of multivalent nanoparticles for use in targeting vascular receptors. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 223, A109-A109.
  
• Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line Armstrong, J. S., Steinauer, K. K., Hornung, B., Irish, J. M., Lecane, P., & Knox, S. J. (2002). Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. CELL DEATH AND DIFFERENTIATION, 9(3), 252-263.
  
• The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation Ning, S. C., Laird, D., Cherrington, J. M., & Knox, S. J. (2002). The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. RADIATION RESEARCH, 157(1), 45-51.
  
• Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW Armstrong, J. S., Hornung, B., Lecane, P., Jones, D. P., & Knox, S. J. (2001). Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 289(5), 973-978.
  
• Radioimmunotherapy of B-cell NHL. Meredith, R. F., & Knox, S. J. (2001). Radioimmunotherapy of B-cell NHL. Current pharmaceutical biotechnology, 2(4), 327-339.
  
• Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., & Vose, J. M. (2001). Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 19(19), 3918-3928.
  
• Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization Armstrong, J. S., Steinauer, K. K., French, J., Killoran, P. L., Walleczek, J., & Knox, S. J. (2001). Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization. EXPERIMENTAL CELL RESEARCH, 262(2), 170-179.
  
• Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University Murtha, A. D., Knox, S. J., Hoppe, R. T., Rupnow, B. A., & Hanson, J. (2001). Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 49(1), 3-15.
  
• Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells Steinauer, K. K., Gibbs, I., Ning, S. C., French, J. N., Armstrong, J., & Knox, S. J. (2000). Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(2), 325-328.
  
• Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96395-induced apoptosis Williams, S. S., French, J. N., Gilbert, M., Rangaswami, A. A., Walleczek, J., & Knox, S. J. (2000). Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96395-induced apoptosis. CANCER RESEARCH, 60(16), 4358-4361.
  
• Clinical radioimmunotherapy Knox, S. J., & Meredith, R. F. (2000). Clinical radioimmunotherapy. SEMINARS IN RADIATION ONCOLOGY, 10(2), 73-93.
  
• Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., & Kaminski, M. S. (2000). Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 18(6), 1316-1323.
  
• Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., & Weiner, L. M. (2000). Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. CLINICAL CANCER RESEARCH, 6(2), 406-414.
  
• Introduction Knox, S. J. (2000). Introduction. Seminars in radiation oncology, 10(2), 71-2.
  
• Radiation absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin Breitz, H. B., Fisher, D. R., Goris, M. L., Knox, S., Ratliff, B., & Weiden, P. L. (1999). Radiation absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 14(5), 381-395.
  
• G(2)/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation Ning, S. C., & Knox, S. J. (1999). G(2)/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. RADIATION RESEARCH, 151(6), 659-669.
  
• The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy Rupnow, B. A., & Knox, S. J. (1999). The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. APOPTOSIS, 4(2), 115-143.
  
• Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system Ning, S. C., Yu, N., Brown, D. M., Kanekal, S., & Knox, S. J. (1999). Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. RADIOTHERAPY AND ONCOLOGY, 50(2), 215-223.
  
• Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor Rupnow, B. A., Murtha, A. D., Chen, E., & Knox, S. J. (1998). Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor. CANCER LETTERS, 127(1-2), 211-219.
  
• Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy Rupnow, B. A., Murtha, A. D., Alarcon, R. M., Giaccia, A. J., & Knox, S. J. (1998). Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. CANCER RESEARCH, 58(9), 1779-1784.
  
• Pretargeted Radioimmunotherapy (TM) with antibody-streptavidin and Y-90 DOTA-Biotin (Avicidin (R)): Result of a dose escalation study. Breitz, H., Knox, S., Weiden, P., Goris, M., Murtha, A., & Reno, J. (1998). Pretargeted Radioimmunotherapy (TM) with antibody-streptavidin and Y-90 DOTA-Biotin (Avicidin (R)): Result of a dose escalation study. JOURNAL OF NUCLEAR MEDICINE, 39(5), 71P-71P.
  
• p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts Rupnow, B. A., Alarcon, R. M., Giaccia, A. J., & Knox, S. J. (1998). p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts. CELL DEATH AND DIFFERENTIATION, 5(2), 141-147.
  
• Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo Ning, S. C., Shui, C. X., Khan, W. B., Benson, W., Lacey, D. L., & Knox, S. J. (1998). Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 40(1), 177-187.
  
• Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts Ning, S. C., Trisler, K., Wessels, B. W., & Knox, S. J. (1997). Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. CANCER, 80(12), 2519-2528.
  
• A prospective study of radiation therapy-associated thrombocytopenia Knox, S. J., Varghese, A., Khan, W., Chen, E., MacManus, M., & Lamborn, K. R. (1997). A prospective study of radiation therapy-associated thrombocytopenia. BLOOD, 90(10), 4237-4238.
  
• Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor Khan, W. B., Shui, C. X., Ning, S. C., & Knox, S. J. (1997). Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. RADIATION RESEARCH, 148(3), 248-253.
  
• Influence of Bcl-2 overexpression on Na+/K+-ATPase pump activity: Correlation with radiation-induced programmed cell death Gilbert, M., & Knox, S. (1997). Influence of Bcl-2 overexpression on Na+/K+-ATPase pump activity: Correlation with radiation-induced programmed cell death. JOURNAL OF CELLULAR PHYSIOLOGY, 171(3), 299-304.
  
• Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model MacManus, M., Lamborn, K., Khan, W., Varghese, A., Graef, L., & Knox, S. (1997). Radiotherapy-associated neutropenia and thrombocytopenia: Analysis of risk factors and development of a predictive model. BLOOD, 89(7), 2303-2310.
  
• Modulation of c-myc activity and apoptosis in vivo Alarcon, R. M., Rupnow, B. A., Graeber, T. G., Knox, S. J., & Giaccia, A. J. (1996). Modulation of c-myc activity and apoptosis in vivo. CANCER RESEARCH, 56(19), 4315-4319.
  
• Treatment of hormone-refractory prostate cancer with Y-90-CYT-356 monoclonal antibody Deb, N., Goris, M., Trisler, K., Fowler, S., Saal, J., & Knox, S. (1996). Treatment of hormone-refractory prostate cancer with Y-90-CYT-356 monoclonal antibody. CLINICAL CANCER RESEARCH, 2(8), 1289-1297.
  
• Association of BCL-2 with membrane hyperpolarization and radioresistance Gilbert, M. S., Saad, A. H., Rupnow, B. A., & Knox, S. J. (1996). Association of BCL-2 with membrane hyperpolarization and radioresistance. JOURNAL OF CELLULAR PHYSIOLOGY, 168(1), 114-122.
  
• Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel Ning, S., Trisler, K., Brown, D. M., Yu, N. Y., Kanekal, S., & Knox, S. J. (1996). Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel. RADIOTHERAPY AND ONCOLOGY, 39(2), 179-189.
  
• Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (tirapazamine) Gilbert, M. S., Rupnow, B. A., Ramirez, D. A., Trisler, K. D., & Knox, S. J. (1996). Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (tirapazamine). CELL DEATH AND DIFFERENTIATION, 3(2), 215-222.
  
• Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., & Levy, R. (1996). Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. CLINICAL CANCER RESEARCH, 2(3), 457-470.
  
• Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody Knox, S., Hoppe, R. T., Maloney, D., Gibbs, I., Fowler, S., & Levy, R. (1996). Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody. BLOOD, 87(3), 893-899.
  
• Overview of studies on experimental radioimmunotherapy. Knox, S. J. (1995). Overview of studies on experimental radioimmunotherapy. Cancer research, 55(23), 5832s-5836s.
  
• (90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma Davis, T. A., Goris, M. L., Trisler, K. D., Negrin, R., Liles, T. M., & Knox, S. (1995). (90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma. BLOOD, 86(10), 1080-1080.
  
• EFFECTS OF STEM-CELL FACTOR ON THE GROWTH AND RADIATION SURVIVAL OF TUMOR-CELLS Shui, C. X., Khan, W. B., Leigh, B. R., Turner, A. M., Wilder, R. B., & Knox, S. J. (1995). EFFECTS OF STEM-CELL FACTOR ON THE GROWTH AND RADIATION SURVIVAL OF TUMOR-CELLS. CANCER RESEARCH, 55(15), 3431-3437.
  
• MULTIPLE COURSES OF HIGH-DOSE TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MANAGEMENT OF MYCOSIS-FUNGOIDES Becker, M., Hoppe, R. T., & Knox, S. J. (1995). MULTIPLE COURSES OF HIGH-DOSE TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MANAGEMENT OF MYCOSIS-FUNGOIDES. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32(5), 1445-1449.
  
• STEM-CELL FACTOR ENHANCES THE SURVIVAL OF MURINE INTESTINAL STEM-CELLS AFTER PHOTON IRRADIATION Leigh, B. R., Khan, W., Hancock, S. L., & Knox, S. J. (1995). STEM-CELL FACTOR ENHANCES THE SURVIVAL OF MURINE INTESTINAL STEM-CELLS AFTER PHOTON IRRADIATION. RADIATION RESEARCH, 142(1), 12-15.
  
• Radioimmunotherapy of the Non-Hodgkin's Lymphomas. Knox, S. J. (1995). Radioimmunotherapy of the Non-Hodgkin's Lymphomas. Seminars in radiation oncology, 5(4), 331-341.
  
• STEM-CELL FACTOR ENHANCES THE SURVIVAL OF IRRADIATED HUMAN BONE-MARROW MAINTAINED IN SCID MICE Leigh, B. R., Webb, S., Hancock, S. L., & Knox, S. J. (1994). STEM-CELL FACTOR ENHANCES THE SURVIVAL OF IRRADIATED HUMAN BONE-MARROW MAINTAINED IN SCID MICE. STEM CELLS, 12(4), 430-435.
  
• ORGAN MODELING IN THE QUANTITATION OF PLANAR IMAGES FOR DISTRIBUTION STUDIES Goris, M. L., Knox, S. A., Nielsen, K. R., & BOUILLANT, O. (1994). ORGAN MODELING IN THE QUANTITATION OF PLANAR IMAGES FOR DISTRIBUTION STUDIES. CANCER, 73(3), 919-922.
  
• EFFECT OF FILGRASTIM (G-CSF) IN HODGKINS-DISEASE PATIENTS TREATED WITH RADIATION Knox, S. J., Fowler, S., Marquez, C., & Hoppe, R. T. (1994). EFFECT OF FILGRASTIM (G-CSF) IN HODGKINS-DISEASE PATIENTS TREATED WITH RADIATION. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 28(2), 445-450.
  
• THE HYPOXIC CYTOTOXIN SR-4233 INCREASES THE EFFECTIVENESS OF RADIOIMMUNOTHERAPY IN MICE WITH HUMAN NON-HODGKINS-LYMPHOMA XENOGRAFTS Wilder, R. B., McGann, J. K., SUTHERLAND, W. R., Waller, E. K., Minchinton, A. I., & Knox, S. J. (1994). THE HYPOXIC CYTOTOXIN SR-4233 INCREASES THE EFFECTIVENESS OF RADIOIMMUNOTHERAPY IN MICE WITH HUMAN NON-HODGKINS-LYMPHOMA XENOGRAFTS. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 28(1), 119-126.
  
• DETERMINANTS OF LOW-DOSE RATE EFFECTS ASSOCIATED WITH RADIOIMMUNOTHERAPY Knox, S. J., Sutherland, W., & Goris, M. L. (1993). DETERMINANTS OF LOW-DOSE RATE EFFECTS ASSOCIATED WITH RADIOIMMUNOTHERAPY. ANTIBODY IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS, 6(3), 197-207.
  
• THE EFFECT OF STEM-CELL FACTOR ON IRRADIATED HUMAN BONE-MARROW Leigh, B. R., Hancock, S. L., & Knox, S. J. (1993). THE EFFECT OF STEM-CELL FACTOR ON IRRADIATED HUMAN BONE-MARROW. CANCER RESEARCH, 53(17), 3857-3859.
  
• CORRELATION OF TUMOR SENSITIVITY TO LOW-DOSE-RATE IRRADIATION WITH G2/M-PHASE BLOCK AND OTHER RADIOBIOLOGICAL PARAMETERS Knox, S. J., Sutherland, W., & Goris, M. L. (1993). CORRELATION OF TUMOR SENSITIVITY TO LOW-DOSE-RATE IRRADIATION WITH G2/M-PHASE BLOCK AND OTHER RADIOBIOLOGICAL PARAMETERS. RADIATION RESEARCH, 135(1), 24-31.
  
• LOCAL HYPERTHERMIA AND SR-4233 ENHANCE THE ANTITUMOR EFFECTS OF RADIOIMMUNOTHERAPY IN NUDE-MICE WITH HUMAN COLONIC ADENOCARCINOMA XENOGRAFTS Wilder, R. B., Langmuir, V. K., Mendonca, H. L., Goris, M. L., & Knox, S. J. (1993). LOCAL HYPERTHERMIA AND SR-4233 ENHANCE THE ANTITUMOR EFFECTS OF RADIOIMMUNOTHERAPY IN NUDE-MICE WITH HUMAN COLONIC ADENOCARCINOMA XENOGRAFTS. CANCER RESEARCH, 53(13), 3022-3027.
  
• RADIOBIOLOGY OF RADIOLABELED ANTIBODY THERAPY AS APPLIED TO TUMOR DOSIMETRY Langmuir, V. K., Fowler, J. F., Knox, S. J., Wessels, B. W., SUTHERLAND, R. M., & Wong, J. Yc. (1993). RADIOBIOLOGY OF RADIOLABELED ANTIBODY THERAPY AS APPLIED TO TUMOR DOSIMETRY. MEDICAL PHYSICS, 20(2), 601-610.
  
• Determinants of low dose rate effects associated with radioimmunotherapy. Knox SJ, Sutherland W, & Goris ML. (1993). Determinants of low dose rate effects associated with radioimmunotherapy. Antibody Immunoconjugates and Radiopharmaceuticals, 6.
  
• Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment. Knox SJ, Goris ML, & Wessels BW. (1993). Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment. Radiotherapy Oncology, 25.
  
• THE EFFECT OF UNLABELED MONOCLONAL-ANTIBODY (MAB) ON THE BIODISTRIBUTION OF I-131 ANTIIDIOTYPE MAB IN MURINE B-CELL LYMPHOMA Schiele, J., Knox, S. J., RUEHL, W., & Goris, M. L. (1992). THE EFFECT OF UNLABELED MONOCLONAL-ANTIBODY (MAB) ON THE BIODISTRIBUTION OF I-131 ANTIIDIOTYPE MAB IN MURINE B-CELL LYMPHOMA. RADIOTHERAPY AND ONCOLOGY, 24(3), 169-176.
  
• OVERVIEW OF ANIMAL STUDIES COMPARING RADIOIMMUNOTHERAPY WITH DOSE EQUIVALENT EXTERNAL BEAM IRRADIATION Knox, S. J., Goris, M. L., & Wessels, B. W. (1992). OVERVIEW OF ANIMAL STUDIES COMPARING RADIOIMMUNOTHERAPY WITH DOSE EQUIVALENT EXTERNAL BEAM IRRADIATION. RADIOTHERAPY AND ONCOLOGY, 23(2), 111-117.
  
• THE BIODISTRIBUTION OF IN-111 ANTI-BFGF IN A VARIETY OF TUMORS - CORRELATION WITH CELL-BINDING ASSAYS Knox, S. J., Brown, J. M., McGann, J., Sutherland, W., Goris, M. L., & Gross, J. L. (1991). THE BIODISTRIBUTION OF IN-111 ANTI-BFGF IN A VARIETY OF TUMORS - CORRELATION WITH CELL-BINDING ASSAYS. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 638, 497-502.
  
• RESULTS OF THE 1989 ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY SURVEY Corn, B. W., Taylor, B. W., Knox, S. J., Martz, K. L., & Flynn, D. F. (1991). RESULTS OF THE 1989 ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY SURVEY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 20(6), 1363-1367.
  
• MYCOSIS-FUNGOIDES ARTHROPATHY Berger, R. G., Knox, S. J., Levy, R., Sklar, J. L., Cohen, P., & Reichert, T. (1991). MYCOSIS-FUNGOIDES ARTHROPATHY. ANNALS OF INTERNAL MEDICINE, 114(7), 571-572.
  
• OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES Knox, S. J., Levy, R., Hodgkinson, S., Bell, R., Brown, S., & Reichert, T. (1991). OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES. BLOOD, 77(1), 20-30.
  
• DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES Knox, S. J., Levy, R., MILLER, R. A., UHLAND, W., Schiele, J., & Goris, M. L. (1990). DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES. CANCER RESEARCH, 50(16), 4935-4940.
  
• THE CHANGING FACE OF RADIATION ONCOLOGY Meredith, R. F., Halberg, F. E., & Knox, S. J. (1990). THE CHANGING FACE OF RADIATION ONCOLOGY. SOUTHERN MEDICAL JOURNAL, 83(4), 488-488.
  
• HYPERTHERMIA AND RADIATION-THERAPY IN THE TREATMENT OF RECURRENT MERKEL CELL TUMORS Knox, S. J., & Kapp, D. S. (1988). HYPERTHERMIA AND RADIATION-THERAPY IN THE TREATMENT OF RECURRENT MERKEL CELL TUMORS. CANCER, 62(8), 1479-1486.
  
• 2 INDEPENDENT PATHWAYS OF HELPER ACTIVITY PROVIDED BY A SINGLE T-CELL CLONE Shigeta, M., Takahara, S., Knox, S. J., Ishihara, T., Vitetta, E. S., & Fathman, C. G. (1986). 2 INDEPENDENT PATHWAYS OF HELPER ACTIVITY PROVIDED BY A SINGLE T-CELL CLONE. JOURNAL OF IMMUNOLOGY, 136(1), 34-38.
  
• EFFECT OF THYMOPOIETIN AND INTERLEUKIN-2 ON DEPRESSED MITOGENIC RESPONSIVENESS AND COLONY FORMATION OF LYMPHOCYTES FROM PATIENTS WITH PRELEUKEMIA Knox, S. J., ROSENBLATT, L. S., Anderson, R. W., & Greenberg, B. R. (1986). EFFECT OF THYMOPOIETIN AND INTERLEUKIN-2 ON DEPRESSED MITOGENIC RESPONSIVENESS AND COLONY FORMATION OF LYMPHOCYTES FROM PATIENTS WITH PRELEUKEMIA. THYMUS, 8(1-2), 33-44.
  
• RELATION OF AGE TO LYMPHOCYTE RADIOSENSITIVITY INVITRO Knox, S. J., SHIFRINE, M., ROSENBLATT, L. S., Reeves, J. D., & Woerner, S. (1984). RELATION OF AGE TO LYMPHOCYTE RADIOSENSITIVITY INVITRO. HEALTH PHYSICS, 46(2), 431-433.
  
• STUDIES OF LYMPHOCYTES-T IN PRELEUKEMIC DISORDERS AND ACUTE NONLYMPHOCYTIC LEUKEMIA - INVITRO RADIOSENSITIVITY, MITOGENIC RESPONSIVENESS, COLONY FORMATION, AND ENUMERATION OF LYMPHOCYTIC SUBPOPULATIONS Knox, S. J., Greenberg, B. R., Anderson, R. W., & ROSENBLATT, L. S. (1983). STUDIES OF LYMPHOCYTES-T IN PRELEUKEMIC DISORDERS AND ACUTE NONLYMPHOCYTIC LEUKEMIA - INVITRO RADIOSENSITIVITY, MITOGENIC RESPONSIVENESS, COLONY FORMATION, AND ENUMERATION OF LYMPHOCYTIC SUBPOPULATIONS. BLOOD, 61(3), 449-455.
  
• LYMPHOCYTE ABNORMALITIES IN PRELEUKEMIA .1. DECREASED NK ACTIVITY, ANOMALOUS IMMUNOREGULATORY CELL SUBSETS AND DEFICIENT EBV RECEPTORS Anderson, R. W., Volsky, D. J., Greenberg, B., Knox, S. J., Bechtold, T., & Purtilo, D. T. (1983). LYMPHOCYTE ABNORMALITIES IN PRELEUKEMIA .1. DECREASED NK ACTIVITY, ANOMALOUS IMMUNOREGULATORY CELL SUBSETS AND DEFICIENT EBV RECEPTORS. LEUKEMIA RESEARCH, 7(3), 389-395.
  
• RADIATION-INDUCED INHIBITION OF HUMAN-LYMPHOCYTE BLASTOGENESIS - THE EFFECT OF SUPEROXIDE-DISMUTASE AND CATALASE Knox, S. J., Misra, H. P., SHIFRINE, M., & ROSENBLATT, L. S. (1982). RADIATION-INDUCED INHIBITION OF HUMAN-LYMPHOCYTE BLASTOGENESIS - THE EFFECT OF SUPEROXIDE-DISMUTASE AND CATALASE. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 41(3), 283-294.
  
• Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters. Knox, S. J., Wilson, F. D., Miller, C. H., ROSENBLATT, L. S., & SHIFRINE, M. (1982). Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters. Stem cells, 1(6), 325-344.
  
• ASSESSMENT OF THE INVITRO RADIOSENSITIVITY OF HUMAN PERIPHERAL-BLOOD LYMPHOCYTES Knox, S. J., SHIFRINE, M., & ROSENBLATT, L. S. (1982). ASSESSMENT OF THE INVITRO RADIOSENSITIVITY OF HUMAN PERIPHERAL-BLOOD LYMPHOCYTES. RADIATION RESEARCH, 89(3), 575-589.
  
• GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD - CULTURE REQUIREMENTS AND APPLICATIONS Knox, S. J., Wilson, F. D., Greenberg, B. R., & SHIFRINE, M. (1982). GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD - CULTURE REQUIREMENTS AND APPLICATIONS. JOURNAL OF CELLULAR BIOCHEMISTRY, 18(1), 15-24.
  
• CYTOGENETICS AND GRANULOPOIETIC EFFECTS OF BONE-MARROW FIBROBLASTIC CELLS IN FANCONIS ANEMIA Greenberg, B. R., Wilson, F. D., Woo, L., Knox, S., Jenks, H., & Taplett, J. (1981). CYTOGENETICS AND GRANULOPOIETIC EFFECTS OF BONE-MARROW FIBROBLASTIC CELLS IN FANCONIS ANEMIA. BRITISH JOURNAL OF HAEMATOLOGY, 48(1), 85-93.
  
• INCREASED RADIOSENSITIVITY OF A SUB-POPULATION OF LYMPHOCYTE-T PROGENITORS FROM PATIENTS WITH FANCONI ANEMIA Knox, S. J., Wilson, F. D., Greenberg, B. R., SHIFRINE, M., ROSENBLATT, L. S., & Misra, H. (1981). INCREASED RADIOSENSITIVITY OF A SUB-POPULATION OF LYMPHOCYTE-T PROGENITORS FROM PATIENTS WITH FANCONI ANEMIA. BLOOD, 57(6), 1043-1048.
  
• THE SELECTIVE GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD IN A SEMISOLID CULTURE SYSTEM Knox, S. J., SHIFRINE, M., Wilson, F. D., & ROSENBLATT, L. S. (1981). THE SELECTIVE GROWTH OF HUMAN LYMPHOCYTE-T COLONIES FROM WHOLE-BLOOD IN A SEMISOLID CULTURE SYSTEM. EXPERIMENTAL HEMATOLOGY, 9(9), 926-937.
  
• A WHOLE-BLOOD TECHNIQUE FOR THE QUANTITATION OF CANINE LYMPHOCYTE-T PROGENITORS USING A SEMISOLID CULTURE SYSTEM Wilson, F. D., Dyck, J. A., Knox, S. J., & SHIFRINE, M. (1980). A WHOLE-BLOOD TECHNIQUE FOR THE QUANTITATION OF CANINE LYMPHOCYTE-T PROGENITORS USING A SEMISOLID CULTURE SYSTEM. EXPERIMENTAL HEMATOLOGY, 8(8), 1031-1039.
  
• Cell-mediated immunity in the dog in relation to disease: A review. Knox SJ, & Shifrine M. (1980). Cell-mediated immunity in the dog in relation to disease: A review. Comp Immun Microbiol Infect Dis, 2.
  
• Susceptibility of clinical isolates of Pseudomonas aeruginosa to antimicrobial agents. Hirsh DC, Wiger N, & Knox SJ. (1979). Susceptibility of clinical isolates of Pseudomonas aeruginosa to antimicrobial agents. Pharmacol Ther, 2.
  
• PHARMACOKINETICS OF PENICILLIN-G IN TURKEY Hirsh, D. C., Knox, S. J., CONZELMAN, G. M., & WIGER, N. (1978). PHARMACOKINETICS OF PENICILLIN-G IN TURKEY. AMERICAN JOURNAL OF VETERINARY RESEARCH, 39(7), 1219-1221.